Dr. Adam Waldman, MD
What this data tells you about Dr. Waldman
Dr. Adam Waldman is a cardiovascular disease in Orlando, FL, with 19 years in practice. Based on federal Medicare data, Dr. Waldman performed 3,173 Medicare services across 2,420 unique beneficiaries.
Between the years covered by Open Payments, Dr. Waldman received a total of $47,108 from 33 pharmaceutical and/or device companies across 153 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Waldman is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) | 847 | $89 | $309 |
| Electrocardiogram (EKG), 12-lead | 428 | $11 | $54 |
| Hospital follow-up visit, high complexity | 315 | $94 | $319 |
| EKG interpretation and report | 212 | $6 | $54 |
| Office visit, established patient, complex (40-54 min) | 172 | $132 | $423 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 125 | $10 | $46 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 120 | $15 | $60 |
| Hospital follow-up visit, moderate complexity | 111 | $62 | $185 |
| Prothrombin time test (blood clotting) | 104 | $4 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 94 | $15 | $68 |
| Initial hospital admission, high complexity | 86 | $137 | $620 |
| New patient office visit, complex (60-74 min) | 61 | $156 | $587 |
| New patient office visit (45-59 min) | 53 | $116 | $448 |
| Regadenoson injection (Lexiscan) for heart stress test | 48 | $33 | $265 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 46 | $2 | $12 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 33 | $18 | $80 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 31 | $11 | $82 |
| Ultrasound of heart, follow-up | 31 | $18 | $76 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 28 | $10 | $143 |
| Ultrasound of heart with probe in esophagus, with report | 27 | $81 | $326 |
| Initial hospital admission, moderate complexity | 26 | $99 | $387 |
| Ultrasound of heart blood flow, valves and chambers | 24 | $14 | $56 |
| Echocardiogram, transthoracic | 23 | $129 | $521 |
| Ambulatory blood pressure monitoring, 1 day or longer, with review, interpretation and report | 23 | $11 | $57 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 23 | $142 | $182 |
| Cardiac catheterization | 22 | $232 | $1,455 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 20 | $5 | $23 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 17 | $332 | $987 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 12 | $48 | $142 |
| Office visit, established patient (20-29 min) | 11 | $64 | $220 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (91%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in cardiovascular disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 8% for cardiovascular disease in FL.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Waldman is a clinical cardiology specialist, with moderate Medicare volume, and high industry engagement (speaking/promotional, top 8%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Waldman experienced with office visit, established patient (30-39 min)?
Does Dr. Waldman receive payments from pharmaceutical companies?
How do Dr. Waldman's costs compare to other cardiovascular diseases in Orlando?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology